DWM
CRSP icon

Darwin Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Darwin Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.4K Hold
925
– – 0.01% 234
2026
Q1 		$44K Hold
925
– – 0.01% 232
2025
Q4 		$48.5K Hold
925
– – 0.02% 218
2025
Q3 		$59.9K Buy
925
+462
+100% +$26.5K 0.02% 205
2025
Q2 		$22.5K Hold
463
– – 0.01% 267
2025
Q1 		$18.2K Hold
463
– – 0.01% 315
2024
Q4 		$18.2K Sell
463
-462
-50% -$21.8K 0.01% 315
2024
Q3 		$43.5K Buy
+925
New +$46.9K 0.01% 247
2020
Q2 		– Sell
-425
Closed -$18K – 269
2020
Q1 		$18K Buy
+425
New +$21.9K 0.01% 376

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Darwin Wealth Management's CRSP Position: Q2 2026 in Review

Darwin Wealth Management held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 925 shares worth $50.4K. The position accounts for 0.01% of the portfolio, ranked #234.

Darwin Wealth Management first reported a position in CRSP in Q1 2020 and has held it in 9 quarters since. The position peaked at $59.9K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Darwin Wealth Management held 925 shares of CRISPR Therapeutics worth $50.4K as of Q2 2026.
  • Darwin Wealth Management left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up 0.01% of Darwin Wealth Management's portfolio in Q2 2026, its #234 holding.
  • Darwin Wealth Management first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 9 quarters since.
  • Darwin Wealth Management's CRISPR Therapeutics position peaked at $59.9K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Darwin Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.